ALSO NOTED: Wyeth bullish on late-stage drug; Zeltia forms research arm; and much more...

> Wyeth is bullishly forecasting potential annual sales of the experimental drug bazedoxifene after analyzing late-stage data for osteoporosis and vasomotor symptoms of menopause. Report

> Wyeth has inked a $195 million licensing pact with the UK's Biotica for novel rapamycin analogs. Report

> Spain's Zeltia is creating a separate arm to pursue work in RNAi. The new unit, Sylentis, will explore gene silencing in ophthalmology and digestive systems. Release

> A subsidiary of Zeltia says that its independent data monitoring committee has approved a Phase III clinical trial of Yondelis for ovarian cancer. Report

> Roche has released new data demonstrating the effectiveness of Fuzeon in treatment-experienced HIV patients. Report

> The FDA has fast-tracked Agennix's talactoferrin alfa for cancer/diabetic foot ulcers. Report

> The FDA has approved Berlex's birth control pill Yaz for a new indication: premenstrual dysphoric disorder. Report

> MedImmune has taken its quest to sue Genentech in a patent violation case directly to the Supreme Court. Report

> Inspire Pharmaceuticals says it is continuing talks with the FDA over Prolacria for dry-eye. The agency said earlier this year that it had insufficient data on the drug's efficacy for an approval. Article

And Finally... Can the FDA regulate nanotech effectively? A former FDA official doesn't think so. Article

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.